Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 126 results

Got a patent, now where to validate?

EU22-03-2021Sarah Kostiuk-Smith

For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.

Second medical use: a regulatory perspective

UK08-02-2021Jackie Mulryne

Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.

Pricing, patents and the PMPRB in Canada

Canada14-12-2020Micheline Gravelle and Iris Cheung

Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.

Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?

EU20-05-2020Paul Williams

Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.

Medicinal cannabis: what next for Brazil?

Brazil21-10-2019Ludmila Kawakami and Ana Paula Couto

Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.

Pharma: A Mexican tradeoff

Mexico30-09-2019Margarita Guerrero Gonzalez

While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.

Secondary patents: Moscow mewl

Russia30-09-2019Maxim Sobolev

An intervention by Russia’s IP ombudsman seeks to solve the validity issue over secondary patents, but is it needed, asks Maxim Sobolev of Rouse.

The future of precision medicine part 6: reimbursement

International08-08-2019Daniel Lim

In future, the more efficient targeting of treatments to specific patient populations that will actually benefit from them, could offset the price of more expensive but well targeted and effective treatments that will be suitable for increasingly smaller patient populations. Daniel Lim and Anna Jackson of Kirkland & Ellis explain.

Shire Pharmaceuticals: A culture of excellence

Ireland, Japan21-05-2019

LSIPR provides a look behind the scenes of Shire Pharmaceuticals, the Irish company valued at £46 billion by its acquirer Takeda.

Marketing authorisation: Splitting the bill

US20-05-2019Mark Remus

An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.

Showing 1 to 10 of 126 results

LSIPR